TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00762606

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification cataract extraction surgery
Description: Surgical removal of cataract using phacoemulsification followed by implantation of an AcrySof Intraocular Lens (Model SN60WF)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Small incision cataract surgery
Description: Surgical removal of cataract using small incision cataract surgery (SICS) followed by implantation of a Polymethyl methacrylate(PMMA) Intraocular Lens (Model MZ60BD).
Study: NCT01419730

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 50,000 IU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 50,000 IU

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: Progressive walking and resistance band exercise prescription for a period of 24 weeks
Study: NCT01335165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1102
Description: Single Ascending Dose IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1103
Description: Single Ascending Dose IV or SC
Study: NCT02939469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiologic maneuvers
Description: Subjects will perform~Valsalva maneuver Hand Grip Post exercise cuff occlusion Loud Noise and Skin pinch
Study: NCT03342872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Training: FBS System Mapping and MTFS-I Installation
Description: Core Training will be a blended strategy wherein multiple interventions targeting multiple agency roles are combined to help ASU treatment providers increase their FBS quality. Core Training will be conducted with administrators, supervisors, data managers, and clinical staff. It will contain two 3-hour sessions focusing on FBS System Mapping and MTFS-I Installation. FBS System Mapping will focus on process mapping of existing site policies and practices for assessing family functioning at intake, educating families about intervention strategies and activities, including family members in treatment sessions, and hiring and supporting clinicians trained in and routinely delivering FBS. MTFS-Installation will focus on introducing MTFS-I components and integrating principles of DDDM.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Training & Facilitation: FBS System Mapping and MTFS-I Installation plus monthly on-site meetings
Description: Facilitation will consist of monthly on-site meetings to review progress toward FBS improvements, discuss MTFS-I feedback reports and online resource use, and provide intensive technical assistance for progressing toward site-selected FBS improvement goals. Meetings will involve a subset of site-delegated participants from Core Training sessions to serve as a local change team (quality improvement team). The efficacy of facilitation-guided change teams has been established. Although there are several models for creating change teams, at least three features are common: (1) members represent multiple organizational roles (supervisors, data managers, line staff); (2) focus on data-driven decisions; and (3) use of external expert advisors.
Study: NCT00755781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine Inhalation Solution (CIS)
Description: Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration (up to 3 years)
Study: NCT01909336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.3% Saline in 3.3% dextrose
Description: Hypotonic Solutions: 0.3% Saline in 3.3% dextrose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.45% Saline in 5% dextrose
Description: Hypotonic Solutions: 0.45% Saline in 5% dextrose
Study: NCT02997137

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BOT-01
Description: Amino acid composition with micronutrients, once a day (in the morning) content of a sachet mixed with 200 ml water.~Duration: 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once a day (in the morning) content of a sachet mixed with 200 ml water.~Placebo contains no amino acids and micronutrients and is identical in appearance and solution properties.~Duration: 12 weeks
Study: NCT00778882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VM106
Description: Autologous hematopoietic stem cells with MT-gp91 retroviral vector
Study: NCT01961882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCV-501

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02112279

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor microbiota applied via colonoscopy.
Description: B. Preparation of donor sample 1. Instillation via Colonoscopy~1. Stool mixture is administered into the terminal ileum and cecum through the biopsy channel of a colonoscope while the patient is sedated.~Administer 300-700 ml of slurry through biopsy channel of colonoscope with a piston syringe.
Study: NCT03678935

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low FODMAP diet
Description: The intervention group follows the low FODMAP diet for 4 weeks.
Study: NCT01909336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Saline in 5% dextrose
Description: Isotonic Solutions 0.9% Saline in 5% dextrose
Study: NCT01469013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered orally as background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered orally as background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered orally as background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered orally as background therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Administered orally as background therapy
Study: NCT03085641

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal high flow oxygen therapy
Description: nHFT will be titrated during a first titration night and used at home during the night for 4 weeks consecutively
Study: NCT00862849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Human Insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Study: NCT01351766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicotine Patch
Description: Transdermal Nicotine: Participants will use 8 weeks of the nicotine patch at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to participant's initial nicotine level.
Study: NCT00078962

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GTI-2040
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02466802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Combination of regorafenib and of sildenafil when given to patients with advanced solid tumors. Regorafenib Administration and Treatment Schedule. Regorafenib will be taken orally once daily for the first 21 days of each 28-day cycle. Regorafenib will not be taken on the last 7 days of each cycle. Patients will be instructed as follows: Take regorafenib once daily with a low fat meal that contains less than 30% fat. Take the regorafenib tablets at about the same time each day. Swallow the tablets whole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate
Description: Combination of regorafenib and of sildenafil when given to patients with advanced solid tumors.Sildenafil Administration and Treatment Schedule. Sildenafil will be taken orally once daily at the same time the regorafenib dose is taken for the first 21 days of each 28-day cycle. Sildenafil will not be taken on the last 7 days of each cycle.
Study: NCT03692091

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subacromial Injection
Description: Injection in to subacromial space in the shoulder from anterior portal

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subacromial Injection
Description: Injection in to subacromial space in the shoulder from anterior portal
Study: NCT02000323

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: early enteral nutrition
Description: Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.~The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.~• After catharsis, Standard enteral nutrition liquid regimen will be used step by step.~Patients are targeted to receive calories for 25 kcal/kg/day.~nutrition form: short peptide ,1 kcal/ml,target 200k kcal/day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: modified early enteral nutrition
Description: Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.~* The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.~* After catharsis, Only Normal Saline were given through nasojejunal tube until 2 or more followed requirements were meted (mean arterial pressure≥65mmHg; oxygenation index≥ 300;APCHEII≤8; intra-abdominal pressure \<20mmHg).Then Standard enteral nutrition liquid regimen (Peptisorb Liquid) will be used step by step.~* Patients are targeted to receive calories for 25 kcal/kg/day.
Study: NCT01805635

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01275560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole,per os,500mg, 3 per day during 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CArbosylane
Study: NCT05398835

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online interventions promoting HIV self-testing
Description: 1) viewing an online video promoting HIVST, 2) visiting the project webpage containing demonstration video of how to use HIVST kits, information about local HIV epidemic and benefits of HIV testing and HIVST, and a discussion forum containing positive feedback of HIVST users, and 3) having access to a chargeable HIVST services implemented by the CBO
Study: NCT02644798

Intervention type: OTHER
Intervention: Baseline-recorded data recorded
Description: Baseline-recorded data recorded. Peripheral blood samples were drawn.
Study: NCT04212377

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cells for endometrial cancer
Description: Our study population consists of 8 mEC patients who receive carboplatin / paclitaxel chemotherapy in a weekly schedule on weeks 1, 2, 3 and weeks 5,6 and 7. In week 8, myeloid and plasmacytoid DC (nDC) are loaded with tumor lysate and MUC1 and survivin PepTivators, injected intranodally. An extensive immuno-motoring will be performed on all patients. Patients who show stable disease, partial response, or full response continue with extended three-week chemotherapy regimens with intranodal injections of nDC at weeks 17, 20, and 23.
Study: NCT02294448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qishe Pill
Description: Qishe Pill is a thin 0.15 g film-coated pill, composed of processed Radix Astragali, Muscone, Szechuan Lovage Rhizome, Radix Stephaniae Tetrandrae, Ovientvine, and Calculus Bovis Artifactus, which should be taken orally with water (240mL) after a minimum 10-hour fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qishe Pill
Description: Qishe Pill is a thin 0.15 g film-coated pill, composed of processed Radix Astragali, Muscone, Szechuan Lovage Rhizome, Radix Stephaniae Tetrandrae, Ovientvine, and Calculus Bovis Artifactus, which should be taken orally with water (240mL) after a minimum 10-hour fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qishe Pill
Description: Qishe Pill is a thin 0.15 g film-coated pill, composed of processed Radix Astragali, Muscone, Szechuan Lovage Rhizome, Radix Stephaniae Tetrandrae, Ovientvine, and Calculus Bovis Artifactus, which should be taken orally with water (240mL) after a minimum 10-hour fast
Study: NCT03016741

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: GnRH agonist/antagonist
Description: Given GnRH agonist/antagonist therapy

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: GnRH agonist/antagonist
Description: Given GnRH agonist/antagonist therapy

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: Given by mouth

Intervention type: DRUG
Group type: OTHER
Intervention: Abiraterone Acetate
Description: Given by mouth

Intervention type: DRUG
Group type: OTHER
Intervention: Enzalutamide
Description: Given by mouth
Study: NCT04189107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: High-dose dexamethasone peroperative and postoperative on day 2 and 4
Study: NCT03785145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT10109L
Description: MT10109L will be injected into the LCL.
Study: NCT04189107

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: low dose dexamethasone peroperative and placebo postoperatively on day 2 and 4
Study: NCT04364269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIT-2763 once a day (QD)
Description: Participants will receive VIT-2763 QD at a dose of 60 mg if their body weight is between 40 kg to 59 kg or at a dose of 120 mg if their body weight is between 60 kg and 100 kg, during 12 weeks.
Study: NCT03785145

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be injected into the LCL.
Study: NCT03105336

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: axicabtagene ciloleucel
Description: A single infusion of axicabtagene ciloleucel CAR transduced autologous T cells administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously
Study: NCT04364269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIT-2763 twice a day (BID)
Description: Participants will receive VIT-2763 BID at a dose of 60 mg if their body weight is between 40 kg to 59 kg or at a dose of 120 mg if their body weight is between 60 kg and 100 kg, during 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive hard capsules of Placebo, twice a day.
Study: NCT04963049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocol with Mask
Description: Look at differences in group with facemask and no mask
Study: NCT01387113

Intervention type: OTHER
Intervention: Computed tomography perfusion imaging
Description: As per standard of care at CPMC
Study: NCT02824679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: 0.9%normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: 0.9%normal saline
Study: NCT04173572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE-Life
Description: PACE-Life Groups will occur twice per week for 15 minutes in the first two weeks, progressing to 30-minute walking sessions over the course of the intervention without changes in frequency. The intensity of virtual walks will increase throughout this intervention in a stepwise fashion to create an exercise dose response to maximize impact on CRF.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Data from Fitbit devices will be synced and accessed through Fitbit.com. Participants will be provided account information to view data but will be asked not to change any of the settings as the investigators will be using data for tracking steps/day and minutes spent walking.
Study: NCT03844854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stabilization occlusal splint and manual therapy
Description: Providing stabilization occlusal splint and manual therapy
Study: NCT00576888

Intervention type: OTHER
Intervention: no intervention
Description: no intervention - observational only
Study: NCT00078962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT04228692

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Self-catheterization only
Description: Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posterior tibial nerve stimulation + self-catheterization
Description: Patients self-catheterized after each micturition, noting the volume of each spontaneous micturition as well as the volume obtained by subsequent self-catheterization, until self-catheterization is no longer necessary.~Patients will have 2 sessions per day of PTN (10-20 min) until self-catheterization is no longer necessary.
Study: NCT02255851

Intervention type: DEVICE
Intervention: SENTINEL (Cerebral Protection System)
Study: NCT00760422

Intervention type: DEVICE
Intervention: NIR
Description: Thermometer
Study: NCT03977285

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine
Description: Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: chlorhexidine
Description: Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chlorhexidine
Description: Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
Study: NCT02934412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: Single subcutaneous injection of SHR-1314 at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: Single subcutaneous injection of SHR-1314 at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: Single subcutaneous injection of SHR-1314 at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: Single subcutaneous injection of SHR-1314 at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: Single subcutaneous injection of SHR-1314 at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single subcutaneous injection of placebo at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single subcutaneous injection of placebo at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single subcutaneous injection of placebo at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single subcutaneous injection of placebo at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single subcutaneous injection of placebo at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.
Study: NCT00585455

Intervention type: DRUG
Intervention: sertraline
Description: open label 25-50 mg daily as tolerated
Study: NCT03105336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously
Study: NCT03316326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur-gimeracil-oteracil potassium
Description: 40 mg bid, D1-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2, D1
Study: NCT03758950

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily inhaled placebo for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone
Description: Inhaled Mometasone for 48 weeks (with 4-week washout at study completion)
Study: NCT05739513

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: miRNA analysis in plasma
Description: blood sample

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: miRNA analysis in plasma
Description: blood sample
Study: NCT03316326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 150 mg/m2, D8
Study: NCT04100096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Tablet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study: NCT04065061

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Erinacine A-enriched Hericium Erinaceus Mycelia

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplement was given to the participants.
Study: NCT02741154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction with aromataze inhibitor
Description: letrozole 2.5mg once daily start in the first day of menses for 5days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMG
Description: HMG 300 IU injection once daily start at first day of menses with follow up by trans vaginal ultrasound (TVUS ) till at least three follicles reach 14 mm in diameter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HMG
Description: HMG 300 IU injection once daily start at first day of menses with follow up by trans vaginal ultrasound (TVUS ) till at least three follicles reach 14 mm in diameter
Study: NCT02001519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC4-CDDP4
Description: 4 cycles of Adriamycin 60 mg/m2 and Cyclophosphamide 600 mg/m2 every 3 weeks 4 cycles of cisplatin 75 mg/m2 every 3 weeks